Success Stories: Molecular Visionary: EB1A Approved for Innovator in Analytical Chemistry

Client’s Testimonial:

“Chen Immigration Service has been tremendously helpful, and I cannot thank everyone enough who supported me throughout the I-140 approval process. Their expertise and guidance made a difficult journey much smoother. I highly recommend their services for anyone pursuing EB-2 or EB-1 immigration.”

On May 21^st, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Postdoctoral Research Fellow in the Field of Analytical Chemistry (Approval Notice).

General Field: Analytical Chemistry

Position at the Time of Case Filing: Postdoctoral Research Fellow

Country of Origin: Bangladesh

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: May 21^st, 2025

Processing Time: 14 days (Premium Processing Requested)

Case Summary:

We’re proud to celebrate the EB1A (Alien of Extraordinary Ability) approval of a Bangladeshi scientist whose pioneering research in analytical chemistry is helping redefine drug discovery and therapeutic strategies for neurodegenerative diseases and cancer.

Revolutionizing Therapeutics at the Molecular Level

This client’s expertise lies in analytical chemistry, with a specialization in advanced mass spectrometry techniques, biomarker discovery, and therapeutic targeting of undruggable proteins. Client’s research addresses some of the most pressing challenges in modern medicine—developing diagnostics and treatments for diseases like neurodegenerative disorders, cancer, and metabolic disorders.

Currently engaged in research at a global pharmaceutical company, the client is actively developing multi-omics approaches and next-generation analytical tools that inform early drug discovery and guide biomarker validation in clinical trials. Their work supports both scientific innovation and public health, making significant contributions to future-ready medicine.

Evidence of Extraordinary Ability

This client’s impressive scholarly portfolio includes 15 peer-reviewed journal publications, with multiple articles published in top-tier journals such as Nature Methods, Nature Metabolism, Nature Communications, and PNAS. Client’s research has received 254 citations and includes at least 6 papers ranked among the top 10% or top 1% most cited in the field of Biology & Biochemistry for it’s publication years.

This client has also completed more than 18 peer reviews for high-impact journals like the New England Journal of Medicine and serves on the editorial board of top-tier journals. These invitations reflect their reputation as a leading voice in drug metabolism, pharmacokinetics, and therapeutic innovation.

Their research has been cited by scientists from leading institutions in over 30 countries and has directly influenced studies on neurodegenerative diseases, nanoparticle therapeutics, and neurochemistry.

Recognized and Funded by the Best

The client’s research has attracted funding from premier U.S. and international bodies, including the NIH, NSF, National Cancer Institute, Dana-Farber Cancer Institute, and more.

A Fast-Tracked Approval

Filed on May 7, 2025, and approved on May 21, 2025, this EB1A petition met USCIS’s high bar for excellence with compelling evidence of sustained international acclaim and influence.

We are honored to support extraordinary scientists like this client—those whose work not only advances fundamental science but also reshapes how we diagnose, treat, and ultimately heal. This client’s success is a powerful reminder of the impact that skilled immigration can have on innovation and human health.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.